Cas no 18323-44-9 (Clindamycin)

Clindamycin structure
Clindamycin structure
Product Name:Clindamycin
CAS No:18323-44-9
MF:C18H33ClN2O5S
MW:424.983023405075
MDL:MFCD00072005
CID:51005
PubChem ID:446598
Update Time:2025-07-23

Clindamycin Chemical and Physical Properties

Names and Identifiers

    • Clindamycin
    • Clidamycin Hydrochloride
    • CLINDAMYCIN, BP98
    • 7-cdl
    • chlolincocin
    • CLDM
    • clinimycin
    • dalacinc
    • sobelin
    • (2S,4R)-N-[(1S,2S)-2-Chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide
    • U-21251
    • clindamycine
    • Clindamycin Base
    • UNII-3U02EL437C
    • CLINDAMYCIN [WHO-DD]
    • SCHEMBL3154
    • Clindamycin In 5 Percent Dextrose
    • D10AF01
    • Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-.alpha.-D-galacto-octopyranoside
    • G01AA10
    • Klimicin
    • KDLRVYVGXIQJDK-AWPVFWJPSA-N
    • L-threo-alpha-D-galacto-Octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-((((2S,4R)-1-methyl-4-propyl-2-pyrrolidinyl)carbonyl)amino)-1-thio-
    • HSDB 3037
    • L-threo-D-galacto-Octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-, trans-alpha-
    • Clinimycin (rescinded)
    • L-THREO-.ALPHA.-D-GALACTO-OCTOPYRANOSIDE, METHYL 7-CHLORO-6,7,8-TRIDEOXY-6-(((1-METHYL-4-PROPYL-2-PYRROLIDINYL)CARBONYL)AMINO)-1-THIO-, (2S-TRANS)-
    • Clindamycin [USAN:INN:BAN]
    • L-threo-alpha-D-galacto-Octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-(((1-methyl-4-propyl-2-pyrrolidinyl)carbonyl)amino)-1-thio-, (2S-trans)-
    • AB01275425_02
    • L-threo-?-D-galacto-Octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-[[[(2S,4R)-1-methyl-4-propyl-2-pyrrolidinyl]carbonyl]amino]-1-thio-
    • (2S,4R)-N-[(1S,2S)-2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyl-tetrahydropyran-2-yl]propyl]-1-methyl-4-propyl-pyrrolidine-2-carboxamide
    • 7 Chloro 7 deoxylincomycin
    • CLINDAMYCIN [INN]
    • Chlorlincocin
    • 7-Deoxy-7(S)-chlorolincomycin
    • Clindamycinum [INN-Latin]
    • Clindamycin hydrochloride
    • 18323-44-9
    • A831786
    • ClindaDerm
    • DTXCID102836
    • Clindamicina [INN-Spanish]
    • CLINDAMYCIN [GREEN BOOK]
    • CCG-268941
    • L-threo-.alpha.-D-galacto-Octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-[[[(2S,4R)-1-methyl-4-propyl-2-pyrrolidinyl]carbonyl]amino]-1-thio-
    • EN300-19736038
    • Clindamicina (INN-Spanish)
    • 7-Chloro-7-deoxylincomycin
    • NSC305832
    • 7-Chlorolincomycin
    • CLINDA & IL-12
    • (2S,4R)-N-[(1S,2S)-2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylsulfanyl)oxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide
    • Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-alpha-D-galacto-octopyranoside
    • clindamycini hydrochloridum
    • CLINDAMYCIN [USAN]
    • (2S,4R)-N-[(1S,2S)-2-chloranyl-1-[(2R,3R,4S,5R,6R)-6-methylsulfanyl-3,4,5-tris(oxidanyl)oxan-2-yl]propyl]-1-methyl-4-propyl-pyrrolidine-2-carboxamide
    • AKOS037515852
    • CLINDAMYCIN (MART.)
    • NS00098633
    • SR-05000001477-1
    • DTXSID2022836
    • CLINDAMYCIN [VANDF]
    • 58207-19-5
    • Clindamycine [French]
    • CLINDAMYCIN PHOSPHATE IMPURITY E [EP IMPURITY]
    • GTPL10607
    • methyl 7-chloro-6,7,8-trideoxy-6-{[(4R)-1-methyl-4-propyl-L-prolyl]amino}-1-thio-L-threo-alpha-D-galacto-octopyranoside
    • J01FF01
    • ClindaMed Oral Drops
    • Methyl 7-chloro-6,7,8-trideoxy-6-
    • BIDD:GT0418
    • AB01275425-01
    • Clindamycinum
    • HMS2089A05
    • Clindamycine (INN-French)
    • CLINDAMYCIN [MART.]
    • Dalacin C
    • Clindamycin (USAN/INN)
    • Clindamicina
    • Antirobe
    • C06914
    • SR-05000001477
    • CHEMBL1753
    • Klindan 300
    • CS-11147
    • Clindamycin & Interleukin 12
    • CS-0013163
    • Dalacine
    • Clindamycine [INN-French]
    • D00277
    • L-threo-a-D-galacto-Octopyranoside, methyl7-chloro-6,7,8-trideoxy-6-[[[(2S,4R)-1-methyl-4-propyl-2-pyrrolidinyl]carbonyl]amino]-1-thio-
    • methyl 7-chloro-6,7,8-trideoxy-6-({[(2S,4R)-1-methyl-4-propyl-2-pyrrolidinyl]carbonyl}amino)-1-thio-L-threo-alpha-D-galacto-octopyranoside
    • 7(S)-Chloro-7-deoxylincomycin
    • EINECS 242-209-1
    • CLINDAMYCIN [MI]
    • (2S,4R)-N-((1S,2S)-2-chloro-1-((2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)propyl)-1-methyl-4-propylpyrrolidine-2-carboxamide
    • HY-B1455
    • AM84752
    • U-21,251
    • HMS2089N16
    • (2S,4R)-N-[(1S,2S)-2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylthio)-2-oxanyl]propyl]-1-methyl-4-propyl-2-pyrrolidinecarboxamide
    • U 21251
    • Clindamycinum (INN-Latin)
    • CLINDAMYCIN [HSDB]
    • Clindamycin,(S)
    • 3U02EL437C
    • AB01018248-03
    • Q422273
    • BRD-A43673346-311-07-1
    • DB01190
    • BRD-A43673346-001-01-1
    • SCHEMBL537702
    • 13441-63-9
    • Cleocin (TN)
    • (2S,4R)-N-{2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylsulfanyl)oxan-2-yl]propyl}-1-methyl-4-propylpyrrolidine-2-carboxamide
    • Methyl 7-chloro-6,7,8-trideoxy-6-{[hydroxy(1-methyl-4-propylpyrrolidin-2-yl)methylidene]amino}-1-thiooctopyranoside
    • methyl 7-chloro-6,7,8-trideoxy-6-({[(2S,4R)-1-methyl-4-propylpyrrolidin-2-yl]carbonyl}amino)-1-thio-D-glycero-alpha-D-galacto-octopyranoside
    • PD009752
    • DTXSID90928608
    • CHEBI:3745
    • NS00008463
    • CHEMBL376185
    • G60910
    • Cleocin
    • NCGC00263950-16
    • NCGC00263950-11
    • MDL： MFCD00072005
    • Inchi： 1S/C18H33ClN2O5S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25)/t9-,10+,11-,12+,13-,14+,15+,16+,18+/m0/s1
    • InChI Key： KDLRVYVGXIQJDK-AWPVFWJPSA-N
    • SMILES： Cl[C@@H](C)[C@H]([C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)SC)O)O)O)NC([C@@H]1C[C@@H](CCC)CN1C)=O

Computed Properties

  • Exact Mass: 424.18000
  • Monoisotopic Mass: 460.157
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 4
  • Hydrogen Bond Acceptor Count: 7
  • Heavy Atom Count: 27
  • Rotatable Bond Count: 8
  • Complexity: 502
  • Covalently-Bonded Unit Count: 2
  • Defined Atom Stereocenter Count: 9
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • Topological Polar Surface Area: 128A^2
  • XLogP3: 2.2

Experimental Properties

  • Color/Form: White crystalline powder
  • Density: 1.1184 (rough estimate)
  • Melting Point: 141 - 143 C
  • Boiling Point: 134°C (rough estimate)
  • Flash Point: 628.1 °C at 760 mmHg
  • Refractive Index: 1.6100 (estimate)
  • PSA: 127.56000
  • LogP: 0.71830
  • pka: 7.6(at 25℃)
  • Specific Rotation: D +214° (chloroform)

Clindamycin Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
Axon Medchem
2063-10 mg
Clindamycin
 18323-44-9 100%
10mg
 €75.00 2023-07-10
Axon Medchem
2063-50 mg
Clindamycin
 18323-44-9 100%
50mg
 €150.00 2023-07-10
SHANG HAI MAI KE LIN SHENG HUA Technology Co., Ltd.
C873782-10mg
Clindamycin
 18323-44-9 99%
10mg
 ￥298.00 2022-09-02
SHANG HAI MAI KE LIN SHENG HUA Technology Co., Ltd.
C873782-50mg
Clindamycin
 18323-44-9 99%
50mg
 ￥759.00 2022-09-02
SHANG HAI MAI KE LIN SHENG HUA Technology Co., Ltd.
C873782-250mg
Clindamycin
 18323-44-9 99%
250mg
 ￥2,599.00 2022-09-02
SHANG HAI JI ZHI SHENG HUA Technology Co., Ltd.
X78925-10mg
Clindamycin
 18323-44-9 99%
10mg
 ￥238.0 2023-09-05
SHANG HAI TAO SHU Biotechnology Co., Ltd.
T6447-25 mg
Clindamycin
 18323-44-9 99.52%
25mg
 ￥432.00 2022-04-26
SHANG HAI TAO SHU Biotechnology Co., Ltd.
T6447-50 mg
Clindamycin
 18323-44-9 99.52%
50mg
 ￥640.00 2022-04-26
SHANG HAI TAO SHU Biotechnology Co., Ltd.
T6447-100 mg
Clindamycin
 18323-44-9 99.52%
100MG
 ￥1152.00 2022-04-26
SHANG HAI TAO SHU Biotechnology Co., Ltd.
T6447-200 mg
Clindamycin
 18323-44-9 99.52%
200mg
 ￥2074.00 2022-04-26

Clindamycin Suppliers

Amadis Chemical Company Limited
Gold Member
Audited Supplier Audited Supplier
(CAS:18323-44-9)Clindamycin
Order Number:A812757
Stock Status:in Stock
Quantity:1g
Purity:99%
Pricing Information Last Updated:Monday, 2 September 2024 16:07
Price ($):518.0
Tiancheng Chemical (Jiangsu) Co., Ltd
Gold Member
Audited Supplier Audited Supplier
(CAS:18323-44-9)Clindamycin
Order Number:LE13908
Stock Status:in Stock
Quantity:25KG,200KG,1000KG
Purity:99%
Pricing Information Last Updated:Friday, 20 June 2025 12:09
Price ($):discuss personally

Clindamycin Related Literature

Related Categories

Additional information on Clindamycin

Clindamycin: A Comprehensive Overview of Its Applications and Recent Research Findings

Clindamycin, with the chemical compound identification number CAS no. 18323-44-9, is a significant antibiotic belonging to the lincosamide class. This compound has been widely recognized for its potent activity against a variety of Gram-positive bacteria, making it a cornerstone in the treatment of several infections. The mechanism of action of Clindamycin involves inhibiting bacterial protein synthesis by binding to the 50S ribosomal subunit, thereby preventing the formation of functional proteins essential for bacterial survival.

The clinical applications of Clindamycin are extensive, covering conditions such as skin and soft tissue infections, bone and joint infections, as well as more severe systemic infections like endocarditis and meningitis. Its efficacy against anaerobic bacteria also makes it a valuable therapeutic option in conditions involving mixed aerobic and anaerobic infections. The compound is available in various formulations, including oral capsules, topical creams, and injectable solutions, which enhance its versatility in clinical settings.

In recent years, there has been a growing interest in understanding the pharmacological properties and potential applications of Clindamycin. One area of particular focus is its role in combination therapies. Studies have demonstrated that the synergistic effect of Clindamycin when used alongside other antibiotics can lead to improved outcomes in treating multidrug-resistant bacterial infections. This approach is crucial in addressing the global challenge of antibiotic resistance.

Moreover, research has explored the anti-inflammatory properties of Clindamycin. Beyond its primary role as an antibiotic, this compound has shown promise in modulating inflammatory responses. This finding has opened new avenues for exploring its use in conditions where inflammation plays a significant role, such as rheumatoid arthritis and inflammatory bowel disease. The underlying mechanisms involve interactions with cellular pathways that regulate inflammation, suggesting potential therapeutic benefits beyond infection control.

The development of novel drug delivery systems for Clindamycin is another area where significant advancements have been made. Nanotechnology-based delivery systems have enhanced the bioavailability and targeted action of Clindamycin, allowing for more efficient treatment with reduced side effects. These innovations are particularly important in achieving localized drug delivery, which can minimize systemic toxicity while maintaining therapeutic efficacy.

Epidemiological studies have also highlighted the importance of proper use and stewardship of Clindamycin. Overuse or misuse of this antibiotic can contribute to the development of resistant bacterial strains. Therefore, there is an ongoing emphasis on educating healthcare providers and patients about the appropriate use of antibiotics. This includes adhering to prescribed dosages and completing full courses of treatment to ensure maximal efficacy and minimize resistance development.

The future prospects for Clindamycin are promising, with ongoing research aimed at expanding its therapeutic applications. Investigations into its potential role in antiviral and anticancer therapies are particularly intriguing. While these applications are still in the early stages of exploration, they highlight the broad pharmacological profile of this compound. The ability to repurpose existing drugs like Clindamycin can significantly reduce the time and cost associated with drug development.

In conclusion, Clindamycin, identified by its CAS number CAS no. 18323-44-9, remains a vital antibiotic with diverse clinical applications. Its mechanisms of action, combined with recent research findings on its multifaceted properties, underscore its importance in modern medicine. As new research continues to uncover additional therapeutic potentials and innovative delivery systems, the role of Clindamycin is expected to evolve further, continuing to address critical challenges in infectious diseases and beyond.

18323-44-9 (Clindamycin) Related Products

Recommended suppliers
Amadis Chemical Company Limited
(CAS:18323-44-9)Clindamycin
A812757
Purity:99%
Quantity:1g
Price ($):518.0
Email
Tiancheng Chemical (Jiangsu) Co., Ltd
(CAS:18323-44-9)Clindamycin
LE13908
Purity:99%
Quantity:25KG,200KG,1000KG
Price ($):Inquiry
Email